BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11698307)

  • 1. Correlation of peripheral blood OX40+(CD134+) T cells with chronic graft-versus-host disease in patients who underwent allogeneic hematopoietic stem cell transplantation.
    Kotani A; Ishikawa T; Matsumura Y; Ichinohe T; Ohno H; Hori T; Uchiyama T
    Blood; 2001 Nov; 98(10):3162-4. PubMed ID: 11698307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and differentiation advantages of CD4+ OX40+ T cells from allogeneic hematopoietic stem cell transplantation recipients.
    Shindo T; Ishikawa T; Fukunaga A; Hori T; Uchiyama T
    Biol Blood Marrow Transplant; 2008 Mar; 14(3):268-81. PubMed ID: 18275893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic of regulatory CD25high and activated CD134+ (OX40) T lymphocytes during acute and chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Sanchez J; Casaño J; Alvarez MA; Roman-Gomez J; Martin C; Martinez F; Gomez P; Serrano J; Herrera C; Torres A
    Br J Haematol; 2004 Sep; 126(5):697-703. PubMed ID: 15327522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myasthenia gravis after allogeneic bone marrow transplantation treated with mycophenolate mofetil monitored by peripheral blood OX40+ CD4+ T cells.
    Kotani A; Takahashi A; Koga H; Morita R; Fukuyama H; Ichinohe T; Ishikawa T; Hori T; Uchiyama T
    Eur J Haematol; 2002; 69(5-6):318-20. PubMed ID: 12460238
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation-associated phenotype of CD3 T cells in acute graft-versus-host disease.
    Paz Morante M; Briones J; Canto E; Sabzevari H; Martino R; Sierra J; Rodriguez-Sanchez JL; Vidal S
    Clin Exp Immunol; 2006 Jul; 145(1):36-43. PubMed ID: 16792671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD25 expression distinguishes functionally distinct alloreactive CD4 CD134 (OX40) T-cell subsets in acute graft-versus-host disease.
    Streeter PR; Zhang X; Tittle TV; Schön CN; Weinberg AD; Maziarz RT
    Biol Blood Marrow Transplant; 2004 May; 10(5):298-309. PubMed ID: 15111929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The T-cell activation markers CD30 and OX40/CD134 are expressed in nonoverlapping subsets of peripheral T-cell lymphoma.
    Jones D; Fletcher CD; Pulford K; Shahsafaei A; Dorfman DM
    Blood; 1999 May; 93(10):3487-93. PubMed ID: 10233901
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human CD134 (OX40) expressed on T cells plays a key role for human herpesvirus 6B replication after allogeneic hematopoietic stem cell transplantation.
    Nagamata S; Nagasaka M; Kawabata A; Kishimoto K; Hasegawa D; Kosaka Y; Mori T; Morioka I; Nishimura N; Iijima K; Yamada H; Kawamoto S; Yakushijin K; Matsuoka H; Mori Y
    J Clin Virol; 2018 May; 102():50-55. PubMed ID: 29494951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The importance of graft cell composition in outcome after allogeneic stem cell transplantation in patients with malignant disease.
    Svenberg P; Wang T; Uhlin M; Watz E; Remberger M; Ringden O; Mattsson J; Uzunel M
    Clin Transplant; 2019 Jun; 33(6):e13537. PubMed ID: 30873642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD134 (0X-40) on T cells during the first 100 days following allogeneic bone marrow transplantation as a marker for lymphocyte activation and therapy-resistant graft-versus-host disease.
    Lamb LS; Abhyankar SA; Hazlett L; O'Neal W; Folk RS; Vogt S; Parrish RS; Bridges K; Henslee-Downey PJ; Gee AP
    Cytometry; 1999 Oct; 38(5):238-43. PubMed ID: 10516610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of T cell activation antigen CD134 (OX40) has no predictive value for the occurrence or response to therapy of acute graft-versus-host disease in partial T cell-depleted bone marrow transplantation.
    Gadisseur AP; Gratama JW; Lamers C; van Esser JW; Bolhuis RL; Cornelissen JJ
    Bone Marrow Transplant; 1999 May; 23(10):1013-7. PubMed ID: 10373067
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
    Yamashita K; Horwitz ME; Kwatemaa A; Nomicos E; Castro K; Sokolic R; Foster SF; Garofalo M; Choi U; Ryherd M; Brown MR; Leitman SF; Wayne AS; Fowler DH; Bishop MR; Childs RW; Barrett AJ; Pavletic SZ; Malech HL
    Biol Blood Marrow Transplant; 2006 Jan; 12(1 Suppl 2):22-30. PubMed ID: 16399598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene expression profiling-based identification of CD28 and PI3K as new biomarkers for chronic graft-versus-host disease.
    Lai P; Weng J; Lu Z; Guo R; Luo C; Wu S; Ling W; Geng S; Du X
    DNA Cell Biol; 2011 Dec; 30(12):1019-25. PubMed ID: 21682596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
    Sarantopoulos S; Stevenson KE; Kim HT; Cutler CS; Bhuiya NS; Schowalter M; Ho VT; Alyea EP; Koreth J; Blazar BR; Soiffer RJ; Antin JH; Ritz J
    Blood; 2009 Apr; 113(16):3865-74. PubMed ID: 19168788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients.
    Blazar BR; Sharpe AH; Chen AI; Panoskaltsis-Mortari A; Lees C; Akiba H; Yagita H; Killeen N; Taylor PA
    Blood; 2003 May; 101(9):3741-8. PubMed ID: 12521997
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of killer cell inhibitor receptors on immunocompetent cells with relation to graft-versus-host disease after hematopoietic stem cell transplantation.
    Duan LN; Chen C; Huang SL; Fang JP; Wei J; Bao R; Li Y; Han HX; Li SN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Dec; 11(6):625-32. PubMed ID: 14706148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. National Institutes of Health-Defined Chronic Graft-vs.-Host Disease in Pediatric Hematopoietic Stem Cell Transplantation Patients Correlates With Parameters of Long-Term Immune Reconstitution.
    Lawitschka A; Gueclue ED; Januszko A; Körmöczi U; Rottal A; Fritsch G; Bauer D; Peters C; Greinix HT; Pickl WF; Kuzmina Z
    Front Immunol; 2019; 10():1879. PubMed ID: 31507582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of Foxp3+ T cell subsets involved in incidence of chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Hu Y; Cui Q; Ye Y; Luo Y; Tan Y; Shi J; Huang H
    Hematol Oncol; 2017 Mar; 35(1):118-124. PubMed ID: 26439896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Altered immune reconstitution of B and T cells precedes the onset of clinical symptoms of chronic graft-versus-host disease and is influenced by the type of onset.
    Bohmann EM; Fehn U; Holler B; Weber D; Holler E; Herr W; Hoffmann P; Edinger M; Wolff D
    Ann Hematol; 2017 Feb; 96(2):299-310. PubMed ID: 27942862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cord blood graft composition impacts the clinical outcome of allogeneic stem cell transplantation.
    Wikell H; Ponandai-Srinivasan S; Mattsson J; Gertow J; Uhlin M
    Transpl Infect Dis; 2014 Apr; 16(2):203-12. PubMed ID: 24456214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.